100 related articles for article (PubMed ID: 3012819)
1. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients.
Riess H; Höfling B; von Arnim T; Hiller E
Thromb Res; 1986 Apr; 42(2):235-45. PubMed ID: 3012819
[TBL] [Abstract][Full Text] [Related]
2. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.
Gresele P; Deckmyn H; Arnout J; Lemmens J; Janssens W; Vermylen J
Lancet; 1984 May; 1(8384):991-4. PubMed ID: 6143969
[TBL] [Abstract][Full Text] [Related]
3. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
5. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
Darius H; Lefer AM
Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of collagen induced thromboxane release from platelets of different species: implications for human atherosclerosis models.
Leach CM; Thorburn GD
Prostaglandins; 1982 Jul; 24(1):47-59. PubMed ID: 7122912
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
8. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
Patscheke H; Stegmeier K
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
[No Abstract] [Full Text] [Related]
9. Effects of combination therapy with low-dose aspirin and warfarin on platelet functions after heart valve replacement.
Kobune K; Inoue M; Morikawa M; Tsuboi M; Takanami Y; Iwane Y; Kudo T
Res Commun Chem Pathol Pharmacol; 1991 Nov; 74(2):153-65. PubMed ID: 1811279
[TBL] [Abstract][Full Text] [Related]
10. Increased platelet thromboxane receptor sensitivity in diabetic patients with proliferative retinopathy.
Collier A; Tymkewycz P; Armstrong R; Young RJ; Jones RL; Clarke BF
Diabetologia; 1986 Aug; 29(8):471-4. PubMed ID: 3019811
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
Hamid-Bloomfield S; Whittle BJ
Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
[TBL] [Abstract][Full Text] [Related]
13. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
[TBL] [Abstract][Full Text] [Related]
14. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease.
Riess H; Hiller E; Reinhardt B; Bräuning C
Thromb Res; 1984 Aug; 35(4):371-8. PubMed ID: 6237460
[TBL] [Abstract][Full Text] [Related]
15. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist.
Ritter JM; Doktor HS; Benjamin N; Barrow SE; Stewart-Long P
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():351-4. PubMed ID: 1825568
[TBL] [Abstract][Full Text] [Related]
16. The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor.
Gillard JW; Morton HE; Fortin R; Yoakim C; Girard Y; Lord A; Ethier D; Leveille C; Letts G; Evans J
Prog Clin Biol Res; 1989; 301():579-83. PubMed ID: 2529557
[No Abstract] [Full Text] [Related]
17. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
18. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets.
di Minno G; Bertelé V; Bianchi L; Barbieri B; Cerletti C; Dejana E; de Gaetano G; Silver MJ
Thromb Haemost; 1981 Apr; 45(2):103-6. PubMed ID: 6266066
[TBL] [Abstract][Full Text] [Related]
19. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
20. Desensitization of platelet thromboxane A2/prostaglandin H2 receptors by the mimetic U46619.
Liel N; Mais DE; Halushka PV
J Pharmacol Exp Ther; 1988 Dec; 247(3):1133-8. PubMed ID: 2974487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
